Epidemiological studies have consistently indicated that the prevalence of depression decreases with increasing age. Researchers have debated whether this finding is a real age-dependent decline or an artefact of sampling and assessment.
The current program of research seeks to investigate new and emerging statistical models to develop accurate and efficient diagnostic instruments that measure the latent relationship between internalising (eg. depression, anxiety), externalising (eg.
Men have traditionally reported higher rates of alcohol and other substance use than women, however there is emerging evidence that women’s levels of substance use may be ‘catching up’ to men’s. This study involves a comprehensive review of the international literature to assess if there is evid
This project focuses on a common clinical problem that causes substantial functional, economic, and health impacts; comorbid depression and alcohol use. These conditions are under-treated and peak in young adulthood.
The use of ecstasy is a public health problem and is associated with a range of social costs and harms. Recently, there has been growing concern about the misuse of new psychoactive substances (NPS) designed to mimic the effects of illicit drugs, including ecstasy.
Anxiety, depressive and substance use disorders account for three quarters of the disability attributed to mental disorders. Moreover, research indicates that these disorders are often comorbid, share common risk factors and interact.
Adolescence is a critical period for brain development, with active rewiring of circuitry that is necessary in successful development of “adult” adaptive patterns of behaviour, such as the frontal lobe and its connections.
Depression and CVD are currently ranked three and four in the top 20 causes of burden of disease worldwide, and are elevated to numbers one and two on this list when middle-high income countries, such as Australia, are considered. Several theories can account for the increased risk of these amon
Mental health and substance use disorders account for more years of life lost due to disability than any other disorders. These disorders often occur together (comorbidity), affecting more than 300,000 Australians every year.
Mental health and alcohol/other drug researchers and clinicians must respond to the increased demand for their services, by developing and evaluating treatment programs that address depression and alcohol use disorders, whilst minimising cost and maximising efficient use of clinician time and cli